Germany interrupts Europe's Selincro love-in with negative IQWiG outcome
This article was originally published in Scrip
Executive Summary
Germany has burst Lundbeck's reimbursement bubble by concluding that alcohol dependence drug Selincro (nalmefene) has no proven additional benefit. The decision runs counter to others seen across Europe, notably in the UK where the drug has been enthusiastically received.